D-Finitive Cell Technologies

D-Finitive Cell Technologies is a Singapore-based biotechnology company specializing in the ex vivo expansion of hematopoietic stem cells (HSCs). Spun off from the Agency for Science, Technology and Research (A*STAR) and the National Cancer Centre Singapore (NCCS), the company utilizes its proprietary D-Finitive™ platform to overcome the limitations of umbilical cord blood transplants. Their technology employs specific small molecules to significantly increase the number of functional, high-quality stem cells available for therapy, which traditionally suffers from low cell counts. By enhancing the quantity and quality of HSCs, D-Finitive aims to improve clinical outcomes and engraftment rates for patients with blood cancers and genetic disorders. The company is currently focused on advancing its lead expansion technology toward clinical applications to make life-saving stem cell transplants more accessible.